A fully integrated protein crystallization platform for small-molecule drug discovery

Journal of Structural Biology

Volumn 142, Issue 1, 2003, Pages 207-217

  Hosfield, David ^a   Palan, John ^a   Hilgers, Mark ^a   Scheibe, Daniel ^a   McRee, Duncan E ^a   Stevens, Raymond C ^b  

^a Takeda San Diego Inc   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Automation; Crystallization; Drug discovery; Protein structure; X ray

Indexed keywords

AMINO TERMINAL SEQUENCE; ANALYTIC METHOD; ARTICLE; BACTERIUM CULTURE; CARBOXY TERMINAL SEQUENCE; CHROMATOGRAPHY; COST EFFECTIVENESS ANALYSIS; CRYSTAL; CRYSTALLIZATION; DATA BASE; DRUG INDUSTRY; DRUG STRUCTURE; FUNCTIONAL ASSESSMENT; IMAGE ANALYSIS; INCUBATOR; ION EXCHANGE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN MODIFICATION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; PROTEIN TARGETING; ROBOTICS;

EID: 0037394499     PISSN: 10478477     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-8477(03)00051-0     Document Type: Article

References (50)

1. Aronov A.M., Munagala N.R., Ortiz De Montellano P.R., Kuntz I.D., Wang C.C. Rational design of selective submicromolar inhibitors of Tritrichomonas foetus hypoxanthine-guanine-xanthine phosphoribosyltransferase. Biochemistry. 39:2000;4684-4691.
2. Blundell T.L., Jhoti H., Abell C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discovery. 1:2002;45-54.
3. Brizuela L., Braun P., LaBaer J. FLEXGene repository: from sequenced genomes to gene repositories for high-throughput functional biology and proteomics. Mol. Biochem. Parasitol. 118:2001;155-165.
4. Buchanan S.G. Structural genomics: bridging functional genomics and structure-based drug design. Curr. Opin. Drug. Discovery Dev. 5:2002;367-381.
5. Burley S.K., Bonanno J.B. Structuring the universe of proteins. Annu. Rev. Genom. Hum. Genet. 3:2002;243-262.
6. Carotenuto L., Cartwright J.H., Castagnolo D., Garcia Ruiz J.M., Otalora F. Theory and simulation of buoyancy-driven convection around growing protein crystals in microgravity. Microgravity Sci. Technol. 13:2002;14-21.
7. Claverie J.M., Monchois V., Audic S., Poirot O., Abergel C. In search of new anti-bacterial target genes: a comparative/structural genomics approach. Comb. Chem. High Throughput Screen. 5:2002;511-522.
8. Diller D.J., Redinbo M.R., Pohl E., Hol W.G. A database method for automated map interpretation in protein crystallography. Proteins. 36:1999;526-541.
9. Ding H.T., Ren H., Chen Q., Fang G., Li L.F., Li R., Wang Z., Jia X.Y., Liang Y.H., Hu M.H.et al. Parallel cloning, expression, purification and crystallization of human proteins for structural genomics. Acta Crystallogr. D Biol. Crystallogr. 58:2002;2102-2108.
10. Edwards A.M., Arrowsmith C.H., Christendat D., Dharamsi A., Friesen J.D., Greenblatt J.F., Vedadi M. Protein production: feeding the crystallographers and NMR spectroscopists. Nat. Struct. Biol. 7(Suppl.):2000;970-972.
11. Garman E. Cool data: quantity and quality. Acta Crystallogr. D Biol. Crystallogr. 55:1999;1641-1653.
12. Goodwill K.E., Tennant M.G., Stevens R.C. High-throughput X-ray crystallography for structure-based drug design. Drug Discovery Today (Genom. Suppl.). 6:2001;S113-118.
13. Gussio R., Zaharevitz D.W., McGrath C.F., Pattabiraman N., Kellogg G.E., Schultz C., Link A., Kunick C., Leost M., Meijer L.et al. Structure-based design modifications of the paullone molecular scaffold for cyclin-dependent kinase inhibition. Anticancer Drug Des. 15:2000;53-66.
14. Hauel N.H., Nar H., Priepke H., Ries U., Stassen J.M., Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem. 45:2002;1757-1766.
15. Hendrickson W.A., Horton J.R., LeMaster D.M. Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): a vehicle for direct determination of three-dimensional structure. EMBO J. 9:1990;1665-1672.
16. Hendrickson W.A., Horton J.R., Murthy H.M., Pahler A., Smith J.L. Multiwavelength anomalous diffraction as a direct phasing vehicle in macromolecular crystallography. Basic Life Sci. 51:1989;317-324.
17. Holz C., Hesse O., Bolotina N., Stahl U., Lang C. A micro-scale process for high-throughput expression of cDNAs in the yeast Saccharomyces cerevisiae. Protein Expr. Purif. 25:2002;372-378.
18. Kaldor S.W., Kalish V.J., Davies 2nd J.F., Shetty B.V., Fritz J.E., Appelt K., Burgess J.A., Campanale K.M., Chirgadze N.Y., Clawson D.K.et al. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J. Med. Chem. 40:1997;3979-3985.
19. Karain W.I., Bourenkov G.P., Blume H., Bartunik H.D. Automated mounting, centering and screening of crystals for high-throughput protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 58:2002;1519-1522.
20. Kim C.U., Lew W., Williams M.A., Liu H.T., Zhang L.J., Swaminathan S., Bischofberger N., Chen M.S., Mendel D.B., Tai C.Y.et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc. 119:1997;681-690.
21. Kim E.E., Baker C.T., Dwyer M.D., Murcko M.A., Rao B.G., Tung R.D., Navia M.A. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally available inhibitor of the enzyme. J. Am. Chem. Soc. 117:1995;1181-1182.
22. Klebe G. Recent developments in structure-based drug design. J. Mol. Med. 78:2000;269-281.
23. Krupka H.I., Rupp B., Segelke B.W., Lekin T.P., Wright D., Wu H.C., Todd P., Azarani A. The high-speed hydra-plus-one system for automated high-throughput protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 58:2002;1523-1526.
24. Kuhn P., Wilson K., Patch M.G., Stevens R.C. The genesis of high-throughput structure-based drug discovery using protein crystallography. Curr. Opin. Chem. Biol. 6:2002;704-710.
25. Lamzin V.S., Perrakis A. Current state of automated crystallographic data analysis. Nat. Struct. Biol. 7(Suppl.):2000;978-981.
26. Lesley S.A. High-throughput proteomics: protein expression and purification in the postgenomic world. Protein Expr. Purif. 22:2001;159-164.
27. Maignan S., Mikol V. The use of 3D structural data in the design of specific factor Xa inhibitors. Curr. Top. Med. Chem. 1:2001;161-174.
28. Muchmore S.W., Olson J., Jones R., Pan J., Blum M., Greer J., Merrick S.M., Magdalinos P., Nienaber V.L. Automated crystal mounting and data collection for protein crystallography. Struct. Fold. Des. 8:2000;R243-246.
29. Neamati N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opin. Invest. Drugs. 10:2001;281-296.
30. Ng J.D., Sauter C., Lorber B., Kirkland N., Arnez J., Giege R. Comparative analysis of space-grown and earth-grown crystals of an aminoacyl-tRNA synthetase: space-grown crystals are more useful for structural determination. Acta Crystallogr. D Biol. Crystallogr. 58:2002;645-652.
31. Possee R.D. Baculoviruses as expression vectors. Curr. Opin. Biotechnol. 8:1997;569-572.
32. Rahuel J., Rasetti V., Maibaum J., Rueger H., Goschke R., Cohen N.C., Stutz S., Cumin F., Fuhrer W., Wood J.M.et al. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. 7:2000;493-504.
33. Reich S.H., Melnick M., Davies 2nd J.F., Appelt K., Lewis K.K., Fuhry M.A., Pino M., Trippe A.J., Nguyen D., Dawson H.et al. Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease. Proc. Natl. Acad. Sci. USA. 92:1995;3298-3302.
34. Rupp B., Segelke B.W., Krupka H.I., Lekin T., Schafer J., Zemla A., Toppani D., Snell G., Earnest T. The TB Structural Genomics Consortium crystallization facility: towards automation from protein to electron density. Acta Crystallogr. D Biol. Crystallogr. 58:2002;1514-1518.
35. Santarsiero B.D., Yegian D.T., Lee C.C., Spraggon G., Gu J., Scheibe D.S., Uber D.C., Cornell E.W., Nordmeyer R.A., Kolbe W.F.et al. An approach to rapid protein crystallization using nanodroplets. J. Appl. Crystallogr. 35:2002;278-281.
36. Saraswathi N.T., Sankaranarayanan R., Vijayan M. Effect of stabilizing additives on the structure and hydration of proteins: a study involving monoclinic lysozyme. Acta Crystallogr. D Biol. Crystallogr. 58:2002;1162-1167.
37. Schmid M.B. Structural proteomics: the potential of high-throughput structure determination. Trends Microbiol. 10:2002;S27-31.
38. Schroder J., Henke A., Wenzel H., Brandstetter H., Stammler H.G., Stammler A., Pfeiffer W.D., Tschesche H. Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. J. Med. Chem. 44:2001;3231-3243.
39. Stevens R.C. High-throughput protein crystallization. Curr. Opin. Struct. Biol. 10:2000;558-563.
40. Stevens R.C., Wilson I.A. Tech.Sight: industrializing structural biology. Science. 293:2001;519-520.
41. Stewart L., Clark R., Behnke C. High-throughput crystallization and structure determination in drug discovery. Drug Discovery Today. 7:2002;187-196.
42. Sugahara M., Miyano M. Development of high-throughput automatic protein crystallization and observation system. Tanpakushitsu Kakusan Koso. 47:2002;1026-1032.
43. Terwilliger T.C., Berendzen J. Automated MAD and MIR structure solution. Acta Crystallogr. D Biol. Crystallogr. 55:1999;849-861.
44. Thaisrivongs S., Tomich P.K., Watenpaugh K.D., Chong K.T., Howe W.J., Yang C.P., Strohbach J.W., Turner S.R., McGrath J.P., Bohanon M.J.et al. Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J. Med. Chem. 37:1994;3200-3204.
45. Trakhanov S., Quiocho F.A. Influence of divalent cations in protein crystallization. Protein Sci. 4:1995;1914-1919.
46. Vekilov P.G. Protein crystal growth - Microgravity aspects. Adv. Space Res. 24:1999;1231-1240.
47. von Itzstein M., Wu W.Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Van Phan T., Smythe M.L., White H.F., Oliver S.W.et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 363:1993;418-423.
48. Walkinshaw M.D. Protein targets for structure-based drug design. Med. Res. Rev. 12:1992;317-372.
49. Waszkowycz B. Structure-based approaches to drug design and virtual screening. Curr. Opin. Drug Discovery Dev. 5:2002;407-413.
50. Yasutake Y., Yao M., Tanaka I. High-throughput protein crystallography. Tanpakushitsu Kakusan Koso. 47:2002;1033-1037.